Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Medicamen Biotech
Join Channel
Consolidated Standalone

Medicamen Biotech

₹510.6 10.5 | 2.1%

Market Cap ₹649 Cr.

Stock P/E 52.4

P/B 3.3

Current Price ₹510.6

Book Value ₹ 156.8

Face Value 10

52W High ₹903.5

Dividend Yield 0.2%

52W Low ₹ 356.8

Edit Ratio

Medicamen Biotech Research see more...

Overview Inc. Year: 1993Industry: Pharmaceuticals & Drugs

MEDICAMEN Biotech Ltd is engaged in production of pharmaceutical formulations. The Company is a manufacturer and dealer of various products, consisting of capsules, tablets, liquid syrup and dry syrup (beta lactum and non-beta lactum), ointment and ORS. Its tablets encompass Biperiden Hydrochloride Tablets USP, Bromhexine Hydrochloride Tablets, Calcium Carbonate Tablets USP, Calcium Gluconate Tablets USP and Captopril Tablets BP. Its pills include Alfacalcidol Capsules, Artemether Capsules, Acebrophylline Capsules, Amoxycillin Capsules and Calcium Dobisilate Capsules. Its dry syrup includes Cefadroxil Oral Suspension BP, Cefadroxil Oral Suspension USP and Cefaclor Oral Suspension BP. It has finished formulation plants, one at Bhiwadi (Rajasthan) and other at Haridwar (Uttarakhand). At Haridwar, the Company manufactures non-betalectum variety of merchandise, consisting of iron-folic acid capsules, ointments, lotions, mouth wash and dental care.

Read More..

Medicamen Biotech Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Medicamen Biotech Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 33 33 23 33 34 36 39 42 44 47
Other Income 0 1 0 1 1 1 0 0 1 1
Total Income 33 33 23 34 34 36 39 42 44 47
Total Expenditure 26 26 18 27 28 30 32 35 39 42
Operating Profit 7 7 5 7 6 7 7 7 5 6
Interest 0 0 1 1 1 1 1 1 1 1
Depreciation 1 2 2 2 2 2 2 2 2 2
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 5 5 3 4 4 4 4 5 2 3
Provision for Tax 1 1 0 1 1 0 1 1 1 1
Profit After Tax 4 4 3 4 4 4 4 4 1 2
Adjustments 0 0 0 0 0 -0 0 0 1 0
Profit After Adjustments 4 4 3 4 4 4 4 4 2 2
Adjusted Earnings Per Share 3.5 3.1 2.2 2.9 2.8 3 3.1 3.3 1.8 1.6

Medicamen Biotech Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 123 126 113 115 141 172
Other Income 4 2 1 2 2 2
Total Income 126 127 113 117 143 172
Total Expenditure 105 106 93 91 117 148
Operating Profit 21 21 20 26 27 25
Interest 1 1 2 2 3 4
Depreciation 2 2 3 6 6 8
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 18 18 16 18 17 14
Provision for Tax 5 5 4 3 2 4
Profit After Tax 12 13 12 15 15 11
Adjustments 0 0 0 0 0 1
Profit After Adjustments 12 13 12 15 15 12
Adjusted Earnings Per Share 10.3 10.9 9.9 12.2 11.6 9.8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 23% 4% 0% 0%
Operating Profit CAGR 4% 9% 0% 0%
PAT CAGR 0% 5% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -26% -0% -0% 51%
ROE Average 9% 10% 11% 11%
ROCE Average 11% 12% 15% 15%

Medicamen Biotech Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 87 121 133 146 193
Minority's Interest 0 0 0 0 0
Borrowings 0 2 6 5 1
Other Non-Current Liabilities 1 1 1 1 -0
Total Current Liabilities 49 56 53 73 83
Total Liabilities 137 181 194 225 277
Fixed Assets 24 34 90 92 93
Other Non-Current Assets 16 41 2 2 14
Total Current Assets 96 104 96 123 163
Total Assets 137 181 194 225 277

Medicamen Biotech Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 23 9 3 4 4
Cash Flow from Operating Activities 4 13 13 4 -6
Cash Flow from Investing Activities -15 -37 -18 -8 -6
Cash Flow from Financing Activities -4 19 6 4 29
Net Cash Inflow / Outflow -14 -5 1 -0 17
Closing Cash & Cash Equivalent 9 3 4 4 21

Medicamen Biotech Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 10.28 10.88 9.93 12.19 11.64
CEPS(Rs) 12.17 12.93 11.99 16.92 16.67
DPS(Rs) 1 0.5 1 1 1
Book NAV/Share(Rs) 73.69 97.55 103.33 113.56 147.21
Core EBITDA Margin(%) 14.24 15.52 17.45 20.86 17.28
EBIT Margin(%) 15.42 15.07 15.89 17.36 14.51
Pre Tax Margin(%) 14.29 14.33 14.54 15.67 12.1
PAT Margin (%) 9.81 10.59 10.76 12.9 10.46
Cash Profit Margin (%) 11.61 12.58 13 17.9 14.98
ROA(%) 8.8 8.36 6.46 7.11 5.87
ROE(%) 13.95 12.94 9.89 11.25 9.06
ROCE(%) 19.3 16.54 12.99 12.94 10.86
Receivable days 129.12 135.71 165.97 183.01 166.45
Inventory Days 45.43 46.85 35.88 50.92 93.37
Payable days 161.09 189.02 253.69 316.67 311.49
PER(x) 47.18 16.61 53.78 52.79 56.31
Price/Book(x) 6.58 1.85 5.17 5.67 4.45
Dividend Yield(%) 0.21 0.28 0.19 0.16 0.15
EV/Net Sales(x) 4.65 1.83 5.92 7 5.92
EV/Core EBITDA(x) 27.02 10.7 32.67 31.32 31.13
Net Sales Growth(%) 0 2.36 -10.19 2.42 22.02
EBIT Growth(%) 0 0.04 -5.32 11.9 2
PAT Growth(%) 0 10.52 -8.74 22.82 -1.14
EPS Growth(%) 0 5.85 -8.74 22.82 -4.53
Debt/Equity(x) 0.14 0.1 0.15 0.19 0.14
Current Ratio(x) 1.98 1.84 1.8 1.69 1.98
Quick Ratio(x) 1.67 1.54 1.7 1.36 1.5
Interest Cover(x) 13.68 20.3 11.85 10.32 6.03
Total Debt/Mcap(x) 0.02 0.05 0.03 0.03 0.03

Medicamen Biotech Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 43.6 43.6 43.6 43.21 43.21 43.21 43.21 43.21 43.21 43.21
FII 0.35 0.4 0.35 0.52 0.17 0.19 0.16 0.21 0.21 0.11
DII 0 0 0 1.44 0.2 0.2 0.2 0.2 0.67 0.99
Public 56.06 56.01 56.06 54.84 56.42 56.4 56.44 56.38 55.91 55.69
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 316.67 to 311.49days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 43.21%.
  • Company has a low return on equity of 10% over the last 3 years.
  • Stock is trading at 3.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Medicamen Biotech News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!